chronic plaque psoriasis

Arcutis Biotherapeutics Files for $100 Million IPO
Arcutis Biotherapeutics Files for $100 Million IPO
CP Wire
Arcutis Biotherpeutics
IPOs
ARQ-151
chronic plaque psoriasis
Flag link:
Arcutis Biotherapeutics Files for $100 Million IPO
Arcutis Biotherpeutics
IPOs
ARQ-151
chronic plaque psoriasis
Flag link:
Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis
Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis
CP Wire
Tremfya
Cosentyx
Jannsen
chronic plaque psoriasis
Flag link:
Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis
Tremfya
Cosentyx
Jannsen
chronic plaque psoriasis
Flag link:
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
CP Wire
Janssen Pharmaceuticals
JNJ
chronic plaque psoriasis
Tremfya
Humira
AbbVie
clinical trials
Flag link:
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
Janssen Pharmaceuticals
JNJ
chronic plaque psoriasis
Tremfya
Humira
Flag link:
Why This FDA Approval for Valeant Is Not as Good as First Thought
Why This FDA Approval for Valeant Is Not as Good as First Thought
Yahoo/24-7 Wall St
Valeant Pharmaceuticals
FDA
Siliq
chronic plaque psoriasis
Flag link:
With Siliq approval, can Amgen and AZ's trash become Valeant's treasure?
With Siliq approval, can Amgen and AZ's trash become Valeant's treasure?
Fierce Pharma
Siliq
Amgen
AstraZeneca
Valeant Pharmaceuticals
chronic plaque psoriasis
Flag link:
FDA declines to expand approval of Pfizer arthritis drug
FDA declines to expand approval of Pfizer arthritis drug
Yahoo/Reuters
FDA
Pfizer
Xeljanz
chronic plaque psoriasis
Flag link:
Eli Lilly Uncovers Positive Data from Ixekizumab Studies
Eli Lilly Uncovers Positive Data from Ixekizumab Studies
Yahoo/Zacks
Eli Lilly
ixekizumab
chronic plaque psoriasis
Flag link:
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Yahoo
Pfizer
chronic plaque psoriasis
tofacitinib
Flag link:
Pfizer announces top-line results of two Phase 3 trials of Tofacitinib
Pfizer announces top-line results of two Phase 3 trials of Tofacitinib
Yahoo/Fly on the Wall
Pfizer
tofacitinib
chronic plaque psoriasis
Janus kinase inhibitor
Flag link:
Novartis tests copy of Amgen's Enbrel in late-stage trial
Novartis tests copy of Amgen's Enbrel in late-stage trial
Reuters
Amgen
Enbrel
generics
Sandoz
Novartis
chronic plaque psoriasis
Flag link:
Actelion's psoriasis drug meets main goal in trial
Actelion's psoriasis drug meets main goal in trial
Reuters
Actelion
ponesimod
chronic plaque psoriasis
Flag link: